| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adaptive immune responses are larger and functionally preserved in a hypervaccinated individual
|
Kocher, Katharina
|
|
|
24 |
5 |
p. e272-e274
|
artikel
|
| 2 |
A summer cold
|
De Ambrogi, Marco
|
|
|
24 |
5 |
p. 461
|
artikel
|
| 3 |
Chikungunya seroprevalence, force of infection, and prevalence of chronic disability after infection in endemic and epidemic settings: a systematic review, meta-analysis, and modelling study
|
Kang, Hyolim
|
|
|
24 |
5 |
p. 488-503
|
artikel
|
| 4 |
Correction to Lancet Infect Dis 2023; 23: 856–66
|
|
|
|
24 |
5 |
p. e281
|
artikel
|
| 5 |
Correction to Lancet Infect Dis 2024; 24: 488–503
|
|
|
|
24 |
5 |
p. e281
|
artikel
|
| 6 |
Correction to Lancet Infect Dis 2024; published online Jan 17. https://doi.org/10.1016/S1473-3099(24)00032-X
|
|
|
|
24 |
5 |
p. e281
|
artikel
|
| 7 |
COVID-19 in Palestine
|
Adjerid, Asma'a
|
|
|
24 |
5 |
p. 462
|
artikel
|
| 8 |
Determining force of infection for chikungunya to support vaccine policy development
|
Wilder-Smith, Annika Beate
|
|
|
24 |
5 |
p. 441-442
|
artikel
|
| 9 |
DNDi receives grant to develop treatments for NTDs
|
Bagcchi, Sanjeet
|
|
|
24 |
5 |
p. e285
|
artikel
|
| 10 |
Effectiveness of one dose of killed oral cholera vaccine in an endemic community in the Democratic Republic of the Congo: a matched case-control study
|
Malembaka, Espoir Bwenge
|
|
|
24 |
5 |
p. 514-522
|
artikel
|
| 11 |
Effectiveness of XBB.1.5 vaccines and antiviral drugs against severe outcomes of omicron infection in the USA
|
Lin, Dan-Yu
|
|
|
24 |
5 |
p. e278-e280
|
artikel
|
| 12 |
Efficacy and safety of an early oral switch in low-risk Staphylococcus aureus bloodstream infection (SABATO): an international, open-label, parallel-group, randomised, controlled, non-inferiority trial
|
Kaasch, Achim J
|
|
|
24 |
5 |
p. 523-534
|
artikel
|
| 13 |
Endobronchial tuberculosis
|
Eskandari, Siawosh K
|
|
|
24 |
5 |
p. e343
|
artikel
|
| 14 |
Excess tuberculosis deaths in the WHO European region
|
Burki, Talha
|
|
|
24 |
5 |
p. e287-e288
|
artikel
|
| 15 |
First fatality from Alaskapox virus
|
Devi, Sharmila
|
|
|
24 |
5 |
p. e282
|
artikel
|
| 16 |
Global incidence and mortality of severe fungal disease
|
Ikuta, Kevin S
|
|
|
24 |
5 |
p. e268
|
artikel
|
| 17 |
Global incidence and mortality of severe fungal disease – Author's reply
|
Denning, David W
|
|
|
24 |
5 |
p. e269
|
artikel
|
| 18 |
Guidelines for the management of Toxoplasma gondii infection and disease in patients with haematological malignancies and after haematopoietic stem-cell transplantation: guidelines from the 9th European Conference on Infections in Leukaemia, 2022
|
Aerts, Robina
|
|
|
24 |
5 |
p. e291-e306
|
artikel
|
| 19 |
Inaccessible: health, wealth, governance, and equity in low-income and middle-income countries
|
Keddy, Karen H
|
|
|
24 |
5 |
p. 444-445
|
artikel
|
| 20 |
Infectious Disease Surveillance Update
|
Zwizwai, Ruth
|
|
|
24 |
5 |
p. e289
|
artikel
|
| 21 |
Invasive pneumococcal disease 3 years after introduction of a reduced 1 + 1 infant 13-valent pneumococcal conjugate vaccine immunisation schedule in England: a prospective national observational surveillance study
|
Bertran, Marta
|
|
|
24 |
5 |
p. 546-556
|
artikel
|
| 22 |
Is eradication of influenza B viruses possible?
|
Koutsakos, Marios
|
|
|
24 |
5 |
p. 451-453
|
artikel
|
| 23 |
Is it time to join the oral antibiotics bandwagon?
|
Justo, Julie Ann
|
|
|
24 |
5 |
p. 445-447
|
artikel
|
| 24 |
John Phair
|
Das, Manjulika
|
|
|
24 |
5 |
p. 456
|
artikel
|
| 25 |
Large language models must serve clinicians, not the reverse
|
Armitage, Richard
|
|
|
24 |
5 |
p. 453-454
|
artikel
|
| 26 |
Leptospirosis cases triple in Réunion
|
Boisson-Walsh, Alix
|
|
|
24 |
5 |
p. e286
|
artikel
|
| 27 |
Malaria prevention: advancing clinical trials to policy
|
Laufer, Miriam K
|
|
|
24 |
5 |
p. 439-440
|
artikel
|
| 28 |
Marburg virus disease outbreaks, mathematical models, and disease parameters: a systematic review
|
Cuomo-Dannenburg, Gina
|
|
|
24 |
5 |
p. e307-e317
|
artikel
|
| 29 |
Non-COVID-19 hospitalisation as a negative control outcome in COVID-19 vaccine effectiveness studies
|
Poukka, Eero
|
|
|
24 |
5 |
p. e275
|
artikel
|
| 30 |
Non-COVID-19 hospitalisation as a negative control outcome in COVID-19 vaccine effectiveness studies – Authors' reply
|
Hansen, Christian Holm
|
|
|
24 |
5 |
p. e276
|
artikel
|
| 31 |
Nuria Izquierdo-Useros—fighting the good fight
|
Kazi, Farooq
|
|
|
24 |
5 |
p. 458
|
artikel
|
| 32 |
On the frontline during the COVID-19 pandemic
|
Moody, Joe
|
|
|
24 |
5 |
p. 464
|
artikel
|
| 33 |
Oriol Mitja—the beginning of the end for yaws
|
Kirby, Tony
|
|
|
24 |
5 |
p. 459
|
artikel
|
| 34 |
Outpacing antiviral resistance: new treatments for influenza virus infection
|
Coughlan, Lynda
|
|
|
24 |
5 |
p. 447-449
|
artikel
|
| 35 |
Pox Romana
|
Burki, Talha
|
|
|
24 |
5 |
p. 463
|
artikel
|
| 36 |
Protocol for testing filovirus treatments during outbreaks
|
Nakkazi, Esther
|
|
|
24 |
5 |
p. e283
|
artikel
|
| 37 |
Quadrivalent dengue-virus vaccines: challenges and opportunities for India
|
Medigeshi, Guruprasad R
|
|
|
24 |
5 |
p. e270-e271
|
artikel
|
| 38 |
Quique Bassat—improving paediatric global health
|
Samarasekera, Udani
|
|
|
24 |
5 |
p. 460
|
artikel
|
| 39 |
Research in brief
|
Devi, Sharmila
|
|
|
24 |
5 |
p. e290
|
artikel
|
| 40 |
Risk of death following chikungunya virus disease in the 100 Million Brazilian Cohort, 2015–18: a matched cohort study and self-controlled case series
|
Cerqueira-Silva, Thiago
|
|
|
24 |
5 |
p. 504-513
|
artikel
|
| 41 |
R21/Matrix-M malaria vaccine: a vital tool in the arsenal against malaria, not a silver bullet
|
Ngou, Olivia
|
|
|
24 |
5 |
p. 438-439
|
artikel
|
| 42 |
Safety and efficacy of dihydroartemisinin–piperaquine for intermittent preventive treatment of malaria in pregnant women with HIV from Gabon and Mozambique: a randomised, double-blind, placebo-controlled trial
|
González, Raquel
|
|
|
24 |
5 |
p. 476-487
|
artikel
|
| 43 |
Safety and efficacy of onradivir in adults with acute uncomplicated influenza A infection: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial
|
Yang, Zifeng
|
|
|
24 |
5 |
p. 535-545
|
artikel
|
| 44 |
Sir Michael Anthony Epstein
|
Bagcchi, Sanjeet
|
|
|
24 |
5 |
p. 455
|
artikel
|
| 45 |
The deadly potential of chikungunya virus
|
Salje, Henrik
|
|
|
24 |
5 |
p. 442-444
|
artikel
|
| 46 |
The full value of immunisation against respiratory syncytial virus for infants younger than 1 year: effects beyond prevention of acute respiratory illness
|
Feikin, Daniel R
|
|
|
24 |
5 |
p. e318-e327
|
artikel
|
| 47 |
The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study
|
Schmit, Nora
|
|
|
24 |
5 |
p. 465-475
|
artikel
|
| 48 |
Tobias Welte
|
Venkatesan, Priya
|
|
|
24 |
5 |
p. 457
|
artikel
|
| 49 |
Untold Lassa fever story: a physician's lived experience
|
Lawal, Qudus Olajide
|
|
|
24 |
5 |
p. e277
|
artikel
|
| 50 |
Use of inactivated poliovirus vaccine for poliovirus outbreak response
|
Bandyopadhyay, Ananda S
|
|
|
24 |
5 |
p. e328-e342
|
artikel
|
| 51 |
What is the pandemic potential of avian influenza A(H5N1)?
|
The Lancet Infectious Diseases,
|
|
|
24 |
5 |
p. 437
|
artikel
|
| 52 |
WHO publishes list of medically important antimicrobials
|
Jesudason, Timothy
|
|
|
24 |
5 |
p. e284
|
artikel
|
| 53 |
Will two doses of pneumococcal conjugate vaccine be enough?
|
Russell, Fiona M
|
|
|
24 |
5 |
p. 449-451
|
artikel
|
Tijdschrift beschrijving